Concepts (176)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Coronavirus Infections | 8 | 2020 | 98 | 1.160 |
Why?
|
| Pneumonia, Viral | 8 | 2020 | 103 | 1.160 |
Why?
|
| Intubation, Intratracheal | 3 | 2021 | 74 | 0.870 |
Why?
|
| Hospitalization | 6 | 2022 | 500 | 0.730 |
Why?
|
| Lung | 3 | 2016 | 279 | 0.610 |
Why?
|
| Tobacco Smoke Pollution | 1 | 2016 | 44 | 0.450 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 2016 | 95 | 0.440 |
Why?
|
| Nicotine | 1 | 2016 | 179 | 0.400 |
Why?
|
| Antibodies, Viral | 3 | 2020 | 70 | 0.340 |
Why?
|
| Personnel, Hospital | 2 | 2020 | 12 | 0.330 |
Why?
|
| Hydroxychloroquine | 2 | 2020 | 11 | 0.330 |
Why?
|
| Adult | 20 | 2022 | 10030 | 0.300 |
Why?
|
| Respiratory Insufficiency | 2 | 2019 | 61 | 0.290 |
Why?
|
| Recovery of Function | 2 | 2020 | 251 | 0.280 |
Why?
|
| Humans | 28 | 2022 | 34562 | 0.270 |
Why?
|
| Middle Aged | 19 | 2022 | 12726 | 0.250 |
Why?
|
| Female | 21 | 2022 | 21532 | 0.250 |
Why?
|
| Vaccination | 3 | 2021 | 153 | 0.230 |
Why?
|
| United States | 10 | 2022 | 4278 | 0.230 |
Why?
|
| Male | 20 | 2022 | 20740 | 0.220 |
Why?
|
| Acute Lung Injury | 2 | 2015 | 37 | 0.220 |
Why?
|
| Immunocompromised Host | 2 | 2022 | 54 | 0.220 |
Why?
|
| Critical Illness | 2 | 2021 | 89 | 0.200 |
Why?
|
| Outpatients | 2 | 2021 | 61 | 0.200 |
Why?
|
| Respiration, Artificial | 2 | 2021 | 105 | 0.200 |
Why?
|
| Immunization, Secondary | 1 | 2022 | 14 | 0.180 |
Why?
|
| Laryngoscopy | 1 | 2021 | 41 | 0.180 |
Why?
|
| Length of Stay | 3 | 2019 | 335 | 0.170 |
Why?
|
| Work | 1 | 2020 | 6 | 0.170 |
Why?
|
| Telecommunications | 1 | 2020 | 7 | 0.170 |
Why?
|
| Contact Tracing | 1 | 2020 | 9 | 0.160 |
Why?
|
| Aged | 11 | 2022 | 11022 | 0.160 |
Why?
|
| Community-Acquired Infections | 1 | 2020 | 33 | 0.160 |
Why?
|
| Shock | 1 | 2020 | 34 | 0.160 |
Why?
|
| Leukoencephalopathies | 1 | 2020 | 12 | 0.160 |
Why?
|
| Influenza Vaccines | 1 | 2021 | 90 | 0.160 |
Why?
|
| Environmental Exposure | 1 | 2020 | 91 | 0.150 |
Why?
|
| Beta vulgaris | 1 | 2019 | 11 | 0.150 |
Why?
|
| Inpatients | 1 | 2020 | 88 | 0.150 |
Why?
|
| Ambulatory Care | 1 | 2020 | 113 | 0.150 |
Why?
|
| Influenza, Human | 1 | 2021 | 133 | 0.150 |
Why?
|
| Nitrates | 1 | 2019 | 29 | 0.150 |
Why?
|
| Case-Control Studies | 4 | 2021 | 926 | 0.140 |
Why?
|
| Delivery of Health Care | 1 | 2020 | 176 | 0.140 |
Why?
|
| T-Lymphocytes, Regulatory | 2 | 2015 | 36 | 0.140 |
Why?
|
| Lipopolysaccharides | 2 | 2015 | 122 | 0.140 |
Why?
|
| Survivors | 1 | 2019 | 177 | 0.130 |
Why?
|
| Vaccines, Synthetic | 3 | 2021 | 16 | 0.130 |
Why?
|
| Young Adult | 5 | 2021 | 2831 | 0.130 |
Why?
|
| Adolescent | 6 | 2021 | 3805 | 0.130 |
Why?
|
| Lacerations | 1 | 2015 | 9 | 0.120 |
Why?
|
| Pregnancy | 2 | 2016 | 1069 | 0.110 |
Why?
|
| DNA Modification Methylases | 1 | 2015 | 11 | 0.110 |
Why?
|
| Tendon Injuries | 1 | 2015 | 40 | 0.110 |
Why?
|
| Azacitidine | 1 | 2015 | 29 | 0.110 |
Why?
|
| Infant, Newborn | 2 | 2016 | 730 | 0.110 |
Why?
|
| Quality of Life | 1 | 2021 | 1032 | 0.110 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2015 | 137 | 0.110 |
Why?
|
| Treatment Outcome | 5 | 2021 | 3623 | 0.110 |
Why?
|
| Pneumonia | 1 | 2015 | 70 | 0.110 |
Why?
|
| Animals, Newborn | 1 | 2015 | 143 | 0.110 |
Why?
|
| Enzyme Inhibitors | 1 | 2015 | 185 | 0.110 |
Why?
|
| Time Factors | 4 | 2021 | 2353 | 0.100 |
Why?
|
| Pharyngeal Muscles | 1 | 2013 | 5 | 0.100 |
Why?
|
| Pharyngeal Diseases | 1 | 2013 | 10 | 0.100 |
Why?
|
| Brain | 1 | 2020 | 1032 | 0.100 |
Why?
|
| Lung Transplantation | 1 | 2011 | 14 | 0.090 |
Why?
|
| Inflammation | 2 | 2015 | 557 | 0.080 |
Why?
|
| Lung Diseases | 1 | 2011 | 51 | 0.080 |
Why?
|
| Calcitonin | 1 | 2010 | 4 | 0.080 |
Why?
|
| Protein Precursors | 1 | 2010 | 27 | 0.080 |
Why?
|
| Multicenter Studies as Topic | 2 | 2021 | 120 | 0.080 |
Why?
|
| Ambulatory Care Facilities | 2 | 2020 | 87 | 0.080 |
Why?
|
| Neutrophils | 1 | 2010 | 123 | 0.080 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2015 | 1393 | 0.080 |
Why?
|
| Intensive Care Units | 2 | 2021 | 123 | 0.070 |
Why?
|
| Academic Medical Centers | 2 | 2020 | 168 | 0.070 |
Why?
|
| Cytokines | 1 | 2010 | 269 | 0.070 |
Why?
|
| Alphapapillomavirus | 1 | 2008 | 12 | 0.070 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2021 | 565 | 0.070 |
Why?
|
| Logistic Models | 2 | 2021 | 808 | 0.070 |
Why?
|
| Single-Blind Method | 2 | 2020 | 214 | 0.070 |
Why?
|
| Papillomavirus Infections | 1 | 2008 | 71 | 0.070 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2008 | 169 | 0.060 |
Why?
|
| Head and Neck Neoplasms | 1 | 2008 | 140 | 0.060 |
Why?
|
| Prospective Studies | 2 | 2021 | 2463 | 0.060 |
Why?
|
| Adoptive Transfer | 2 | 2015 | 28 | 0.060 |
Why?
|
| Risk Factors | 3 | 2020 | 4137 | 0.060 |
Why?
|
| Bird Diseases | 1 | 2004 | 1 | 0.050 |
Why?
|
| Songbirds | 1 | 2004 | 1 | 0.050 |
Why?
|
| Disease Reservoirs | 1 | 2004 | 2 | 0.050 |
Why?
|
| West Nile Fever | 1 | 2004 | 2 | 0.050 |
Why?
|
| Severity of Illness Index | 2 | 2021 | 922 | 0.050 |
Why?
|
| Disease Outbreaks | 1 | 2004 | 44 | 0.050 |
Why?
|
| Chemotaxis, Leukocyte | 2 | 2015 | 23 | 0.050 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2020 | 988 | 0.050 |
Why?
|
| Mice, Inbred C57BL | 2 | 2015 | 842 | 0.050 |
Why?
|
| Immunocompetence | 1 | 2022 | 12 | 0.050 |
Why?
|
| Risk Assessment | 2 | 2021 | 1508 | 0.040 |
Why?
|
| Disease Models, Animal | 2 | 2015 | 1129 | 0.040 |
Why?
|
| Health Facilities | 1 | 2021 | 15 | 0.040 |
Why?
|
| Trachea | 1 | 2021 | 56 | 0.040 |
Why?
|
| Infectious Disease Transmission, Professional-to-Patient | 1 | 2020 | 4 | 0.040 |
Why?
|
| Seroepidemiologic Studies | 1 | 2020 | 10 | 0.040 |
Why?
|
| Antimalarials | 1 | 2020 | 8 | 0.040 |
Why?
|
| Treatment Failure | 1 | 2020 | 170 | 0.040 |
Why?
|
| Corpus Callosum | 1 | 2020 | 18 | 0.040 |
Why?
|
| Cross Infection | 1 | 2020 | 62 | 0.040 |
Why?
|
| Nitrites | 1 | 2019 | 22 | 0.040 |
Why?
|
| Disease Progression | 1 | 2021 | 634 | 0.040 |
Why?
|
| Subacute Care | 1 | 2019 | 18 | 0.040 |
Why?
|
| Acute Disease | 1 | 2019 | 277 | 0.040 |
Why?
|
| Socioeconomic Factors | 1 | 2020 | 446 | 0.040 |
Why?
|
| Physical Therapy Modalities | 1 | 2019 | 84 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2020 | 755 | 0.040 |
Why?
|
| Chi-Square Distribution | 1 | 2019 | 305 | 0.040 |
Why?
|
| Double-Blind Method | 1 | 2019 | 597 | 0.030 |
Why?
|
| Dietary Supplements | 1 | 2019 | 198 | 0.030 |
Why?
|
| Critical Care | 1 | 2019 | 113 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2019 | 585 | 0.030 |
Why?
|
| Sex Factors | 1 | 2019 | 708 | 0.030 |
Why?
|
| Animals | 3 | 2015 | 8579 | 0.030 |
Why?
|
| Rupture | 1 | 2015 | 36 | 0.030 |
Why?
|
| Chemokine CCL5 | 1 | 2015 | 7 | 0.030 |
Why?
|
| Chemokine CXCL10 | 1 | 2015 | 2 | 0.030 |
Why?
|
| Forkhead Transcription Factors | 1 | 2015 | 27 | 0.030 |
Why?
|
| Retrospective Studies | 2 | 2015 | 3825 | 0.030 |
Why?
|
| Interleukin-10 | 1 | 2015 | 31 | 0.030 |
Why?
|
| Rotator Cuff | 1 | 2015 | 77 | 0.030 |
Why?
|
| Homeodomain Proteins | 1 | 2015 | 55 | 0.030 |
Why?
|
| Bronchoalveolar Lavage Fluid | 1 | 2015 | 62 | 0.030 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 1 | 2015 | 51 | 0.030 |
Why?
|
| Chemokine CCL2 | 1 | 2015 | 52 | 0.030 |
Why?
|
| Monocytes | 1 | 2015 | 141 | 0.030 |
Why?
|
| Mice, Knockout | 1 | 2015 | 486 | 0.030 |
Why?
|
| Phenotype | 1 | 2015 | 657 | 0.020 |
Why?
|
| Surgical Stapling | 1 | 2013 | 9 | 0.020 |
Why?
|
| South Carolina | 1 | 2013 | 31 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2015 | 889 | 0.020 |
Why?
|
| Endoscopy | 1 | 2013 | 56 | 0.020 |
Why?
|
| Laser Therapy | 1 | 2013 | 57 | 0.020 |
Why?
|
| Reoperation | 1 | 2013 | 265 | 0.020 |
Why?
|
| Hospital Charges | 1 | 2011 | 16 | 0.020 |
Why?
|
| Baltimore | 1 | 2011 | 50 | 0.020 |
Why?
|
| Calcitonin Gene-Related Peptide | 1 | 2010 | 12 | 0.020 |
Why?
|
| Creatinine | 1 | 2011 | 206 | 0.020 |
Why?
|
| Interleukin-1beta | 1 | 2010 | 44 | 0.020 |
Why?
|
| Shock, Septic | 1 | 2010 | 26 | 0.020 |
Why?
|
| Glomerular Filtration Rate | 1 | 2011 | 315 | 0.020 |
Why?
|
| Linear Models | 1 | 2011 | 465 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 2010 | 281 | 0.020 |
Why?
|
| Hospital Mortality | 1 | 2011 | 207 | 0.020 |
Why?
|
| Interleukin-6 | 1 | 2010 | 258 | 0.020 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2010 | 227 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2011 | 703 | 0.020 |
Why?
|
| Comorbidity | 1 | 2011 | 596 | 0.020 |
Why?
|
| Tongue Neoplasms | 1 | 2008 | 5 | 0.020 |
Why?
|
| Sepsis | 1 | 2010 | 167 | 0.020 |
Why?
|
| Tonsillar Neoplasms | 1 | 2008 | 6 | 0.020 |
Why?
|
| Mice | 1 | 2015 | 2720 | 0.020 |
Why?
|
| RNA, Viral | 1 | 2008 | 49 | 0.020 |
Why?
|
| DNA, Viral | 1 | 2008 | 57 | 0.020 |
Why?
|
| Oropharyngeal Neoplasms | 1 | 2008 | 23 | 0.020 |
Why?
|
| Papillomavirus Vaccines | 1 | 2008 | 44 | 0.020 |
Why?
|
| Postoperative Complications | 1 | 2013 | 850 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2008 | 326 | 0.020 |
Why?
|
| Alcohol Drinking | 1 | 2008 | 261 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2013 | 4157 | 0.010 |
Why?
|
| Smoking | 1 | 2008 | 544 | 0.010 |
Why?
|
| West Nile virus | 1 | 2004 | 2 | 0.010 |
Why?
|
| Chicago | 1 | 2004 | 10 | 0.010 |
Why?
|
| Sentinel Surveillance | 1 | 2004 | 10 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2008 | 1910 | 0.010 |
Why?
|
| Infant | 1 | 2004 | 1123 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2004 | 1355 | 0.010 |
Why?
|
| Child | 1 | 2004 | 2614 | 0.010 |
Why?
|